Summary & Overview
HCPCS Q2058: Obecabtagene autoleucel, CAR T-cell Infusion per Dose
HCPCS Level II code Q2058 designates Obecabtagene autoleucel, an autologous CD19-directed CAR T-cell therapy provided in doses of 10 to 400 million CAR-positive viable T cells, and explicitly bundles leukapheresis and dose preparation per infusion. This code captures a high-cost, complex cellular immunotherapy that is clinically used for B‑cell malignancies and other CD19-expressing disorders, making it a focal point for payer policy, site-of-care decisions, and reimbursement negotiation nationally.
Key national payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical and billing scope for Q2058, how the service line and typical sites of care align with hospital-based infusion and inpatient settings, and what stakeholders commonly evaluate when coding and accepting claims for CAR T-cell infusions. The publication highlights typical service components bundled by the code, common modifiers that may be applied, and areas where policy updates and utilization management intersect with clinical practice.
This summary provides benchmarks and contextual guidance for revenue cycle, clinical operations, and payer relations teams preparing for claims, authorization, and site-of-service planning for Obecabtagene autoleucel infusions.
Billing Code Overview
HCPCS Level II code Q2058 describes Obecabtagene autoleucel, specified as a cellular therapy product delivered in doses of 10 up to 400 million CD19 CAR-positive viable T cells. The code description explicitly includes leukapheresis and dose preparation procedures, per infusion, indicating a bundled service that covers the cell collection and preparation steps associated with each infusion.
Service Type: Autologous CAR T-cell therapy with leukapheresis and dose preparation, per infusion
Typical Site of Service: Hospital inpatient or hospital outpatient infusion center
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who has failed at least two prior lines of systemic therapy is evaluated for autologous CD19-directed CAR T-cell therapy. The workflow includes referral to a tertiary cancer center, pre-treatment eligibility assessment (performance status, organ function, infectious disease screening), leukapheresis to collect peripheral blood mononuclear cells, cell processing and manufacture of obecabtagene autoleucel product, lymphodepleting chemotherapy (typically fludarabine and cyclophosphamide) administered prior to infusion, inpatient or observation-unit admission for the CAR T-cell infusion, and post-infusion monitoring for cytokine release syndrome (CRS), neurotoxicity, infections, and other complications. The billed HCPCS Level II code Q2058 represents the obecabtagene autoleucel dose (10 up to 400 million CD19 CAR‑positive viable T cells) and expressly includes leukapheresis and dose preparation procedures per infusion. Typical sites of service are an inpatient hospital or specialized outpatient infusion center within a hospital or comprehensive cancer center experienced in CAR T-cell therapies. Typical patient scenario: a patient admitted same-day or overnight for lymphodepletion, receives the Q2058 infusion on the scheduled day, remains under close monitoring for 7–14 days with access to critical care if CRS or neurotoxicity occurs, and has scheduled follow-up visits for disease response assessment and long-term monitoring for delayed adverse events.
Coding Specifications
| Modifier | Description |
|---|